null
100% Quality Guarantee
PhD-Level Technical Support
Key Features

Anti-Alpha-A Crystallin Antibody [1H3.B8]

SKU STMA00025
Antibody Type Monoclonal
Applications WB
Applications ELISA
Applications ICC/IF
Reactivity Human
Reactivity Mouse
Reactivity Rat
Reactivity Bovine
Host Species Mouse
Isotype IgG1
€592
Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

Alpha-A Crystallin Antibody [1H3.B8]

Alpha-A Crystallin Antibody [1H3.B8] is a mouse monoclonal antibody directed against Alpha-A Crystallin, offered by Assay Genie for research applications. Reported applications include WB, ELISA and ICC/IF. Reported reactivity: Human, Mouse, Rat and Bovine. Supplied as IgG1, purified by Protein G.

Alpha A Crystallin (CRYAA) is a member of the small heat shock protein (sHSP) family and a major structural component of the vertebrate eye lens. Traditionally recognized for its role in maintaining lens transparency and refractive properties, CRYAA is now gaining attention in neuroscience for its molecular chaperone activity and neuroprotective potential. CRYAA prevents protein aggregation by binding to partially unfolded or denatured proteins, a function critical in the context of neurodegenerative diseases characterized by protein misfolding, such as Alzheimer’s, Parkinson’s, and Huntington’s disease. Under cellular stress, CRYAA undergoes phosphorylation, enhancing its chaperone function and contributing to protein homeostasis. Beyond the lens, CRYAA is expressed in various tissues and interacts with a wide range of cellular components, including membrane proteins, nuclear proteins, Golgi matrix proteins, and even DNA. These interactions suggest broader roles in intracellular architecture, signal transduction, and genomic stability. Importantly, both Alpha A and Alpha B Crystallins exhibit anti-apoptotic properties by inhibiting caspase activation, positioning them as potential modulators of neuronal survival. CRYAA’s autokinase activity and involvement in cytoskeletal dynamics further support its relevance in maintaining neuronal integrity under stress. As interest grows in targeting molecular chaperones for neurodegenerative therapy, CRYAA stands out as a promising candidate for biomarker development, therapeutic delivery, and cellular resilience enhancement in the aging and diseased brain. This antibody is also available conjugated to ATTO 390, ATTO 488, ATTO 594, APC, Biotin, FITC, HRP, PerCP and RPE. Supplied in 200 µg. For research use only; not for diagnostic or therapeutic procedures.

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose